Table III.
Analysis of the secondary trait prostate specific antigen in the case–control study of prostate cancer: test of no genetic effect.
| CHR | SNP | γ01γ1 | Test 1 (×10−4) | Test 2 (×10−4) | Test 3 (×10−4) | MinT (×10−4) |
|---|---|---|---|---|---|---|
| 2 | rs10197545 | 0.704 | 0.953 0.953 |
0.552 0.400 |
0.729 0.460 |
0.953 |
| 3 | rs17034929 | −0.037 | 2.20 2.20 |
0.467 0.674 |
0.150 0.446 |
2.20 |
| 6 | rs9448387 | 0.687 | 1.40 1.40 |
0.93 0.449 |
1.33 0.480 |
1.40 |
| 10 | rs2255684 | 0.550 | 0.421 0.421 |
0.479 0.478 |
1.00 0.590 |
1.00 |
| 12 | rs7135149 | −0.150 | 1.46 1.46 |
0.675 1.50 |
0.465 1.44 |
1.46 |
| 12 | rs11068651 | 0.414 | 0.600 0.600 |
0.246 0.250 |
0.199 0.240 |
0.600 |
| 13 | rs9594159 | −0.022 | 7.41 7.41 |
1.98 3.91 |
0.776 2.40 |
7.41 |
| 13 | rs9316673 | 0.462 | 0.215 0.215 |
0.048 0.054 |
0.025 0.040 |
0.215 |
| 19 | rs350134 | 0.095 | 4.06 4.06 |
1.66 2.20 |
0.990 1.90 |
4.06 |
CHR, Chromosome. SNP, single nucleotide polymorphism; Test 1, p-value of the Wald test assuming τ2 = 0; Test 2, p-value of the Wald test assuming τ2 = 0.05 × 0.95; Test 3, p-value of the Wald test assuming τ2 = 0.1 × 0.9. MinT, p-value of the minimum test for the baseline prevalence rate ranging from 0% to 10% evaluated at an interval of 0.2%. The second entry is the maximum likelihood approach.